I studier med patienter, der ikke tidligere har været behandlet med nukleosid, sås under behandling ALAT- stigninger > 10 gange ULN og > 2 gange baseline hos 2% af de entecavir- behandlede patienter vs 4% af de lamivudin- behandlede patienter.
Exacerbations during treatment: in studies with nucleoside naive patients, on treatment ALT elevations > 10 times ULN and > 2 times baseline occurred in 2% of entecavir treated patients vs 4% of lamivudine treated patients.